Study Evaluation LXR-623 in Healthy Adults

A Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of LXR-623 Administered Orally to Healthy Subjects

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00379860

Enrollment

Unknown

Registered

2006-09-25

Start date

2006-10-31

Completion date

2007-01-31

Last updated

2007-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects

Brief summary

To evaluate the safety and tolerability of multiple doses of LXR in healthy adults.

Interventions

DRUGLXR-623

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Generally healthy adults. * Liver function tests, triglycerideres, and creatinine must be below upper limit of normal at screening.

Exclusion criteria

* A history or active presence of clinically important medical disease. * Any metal implants or devices. * Claustrophobia.

Design outcomes

Primary

Measure	Time frame
Safety is the primary outcome.	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026